2 news items
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
of 7.5 months.PSA reductions of ≥ 50% were observed in 36% of PSA evaluable patients. Safety analysis: The most
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
FG-3246 demonstrated an acceptable safety profile; adverse events consistent
- Prev
- 1
- Next